Gastrointestinal Cancers

Web Exclusives | December 14, 2021
In a follow-up analysis, second-line nivolumab in advanced/recurrent esophageal squamous-cell carcinoma showed significant median overall survival benefit compared with chemotherapy.
Web Exclusives | December 14, 2021
Promising antitumor activity and a tolerable safety profile were found in patients with previously treated gastric or gastroesophageal cancer treated with trifluridine/tipiracil combined with ramucirumab.
Web Exclusives | December 14, 2021
Insertion-deletion rate and high tumor mutation burden in advanced gastric cancer was found to be associated with favorable progression-free survival and overall survival in patients treated with nivolumab.
Web Exclusives | December 14, 2021
Treatment with surufatinib in combination with toripalimab is associated with promising responses and manageable adverse events in previously treated gastric or gastroesophageal junction adenocarcinoma.
Web Exclusives | December 14, 2021
Post-hoc analysis of the CheckMate-032 study found PD-L1 expression by combined positive score was more closely associated with nivolumab and ipilimumab therapy efficacy compared with percentage of positive tumor cells PD-L1 expression in advanced gastric/gastroesophageal junction cancer.
Web Exclusives | December 14, 2021
Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy.
Web Exclusives | December 14, 2021
Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy.
Web Exclusives | December 14, 2021
Nivolumab with paclitaxel plus ramucirumab as second-line therapy in patients with advanced gastric cancer demonstrated promising responses with manageable treatment-related adverse events.
Web Exclusives | November 16, 2021
Nivolumab plus chemotherapy in patients with advanced gastric cancer, esophageal adenocarcinoma, or gastroesophageal junction cancer led to significantly higher health-related quality-of-life scores than in patients receiving chemotherapy alone.
Web Exclusives | November 16, 2021
KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy.
Page 1 of 3
Results 1 - 10 of 21

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code